COMPARATIVE SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-058
• By: KAO, Chi-Lan (cathay general hospital, pharmacy, China Taiwan)
• Co-author(s): Chi-Lan Kao: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
  Tsai-Ling Chiang: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
  Ting-Ching Wu: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
  Wan-Tsui Huang: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan;School of Pharmacy, Taipei Medical University, taipei, China Taiwan
  
• Abstract:

  Background

  Safety of different direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, edoxaban and apixaban) in patients with non-valvular atrial fibrillation (NVAF) has not been evaluated in clinical practice.

  .

  Methods

  This was a retrospective cohort study. We included patients with NVAF who initiated any of DOACs in the Cathay General
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login